Why the study?
Does a diet rich in medium-chain fatty acids improve cardiac steatosis and function in patients with type 2 diabetes compared to a diet rich in long-chain fatty acids?
Does a diet rich in medium-chain fatty acids improve cardiac steatosis and function in patients with type 2 diabetes compared to a diet rich in long-chain fatty acids?
A short-term diet rich in medium-chain fatty acids may improve cardiac contractility and alter the plasma lipidome in patients with type 2 diabetes compared to a long-chain fatty acid diet.
Answers are grounded in this paper and cite their sources.
MCFA-rich diets may support cardiac contractility in T2D; extends dietary fat-type effects on myocardial function to RCT evidence.
CONTEXT: Excessive cardiac long-chain fatty acid (LCFA) metabolism/storage causes cardiomyopathy in animal models of type 2 diabetes. Medium-chain fatty acids (MCFAs) are absorbed and oxidized efficiently. Data in animal models of diabetes suggest MCFAs may benefit the heart. OBJECTIVE: Our objective was to test the effects of an MCFA-rich diet vs an LCFA-rich diet on plasma lipids, cardiac steatosis, and function in patients with type 2 diabetes. DESIGN: This was a double-blind, randomized, 2-week matched-feeding study. SETTING: The study included ambulatory patients in the general community. PATIENTS: Sixteen patients, ages 37-65 years, with type 2 diabetes, an ejection fraction greater than 45%, and no other systemic disease were included. INTERVENTION: Fourteen days of a diet rich in MCFAs or LCFAs, containing 38% as fat in total, was undertaken. MAIN OUTCOME MEASURES: Cardiac steatosis and function were the main outcome measures, with lipidomic changes considered a secondary outcome. RESULTS: The relatively load-independent measure of cardiac contractility, S', improved in the MCFA group (P < .05). Weight-adjusted stroke volume and cardiac output decreased in the LCFA group (both P < .05). The MCFA, but not the LCFA, diet decreased several plasma sphingolipids, ceramide, and acylcarnitines implicated in diabetic cardiomyopathy, and changes in several sphingolipids correlated with improved fasting insulins. CONCLUSIONS: Although a diet high in MCFAs does not change cardiac steatosis, our findings suggest that the MCFA-rich diet alters the plasma lipidome and may benefit or at least not harm cardiac function and fasting insulin levels in humans with type 2 diabetes. Larger, long-term studies are needed to further evaluate these effects in less-controlled settings.
No takes yet. Share an insight, caveat, or question.
Airhart et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: